JP7294661B2 - ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス - Google Patents

５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス Download PDF

Info

Publication number
JP7294661B2
JP7294661B2 JP2019534154A JP2019534154A JP7294661B2 JP 7294661 B2 JP7294661 B2 JP 7294661B2 JP 2019534154 A JP2019534154 A JP 2019534154A JP 2019534154 A JP2019534154 A JP 2019534154A JP 7294661 B2 JP7294661 B2 JP 7294661B2
Authority
JP
Japan
Prior art keywords
compound
formula
solvent
reaction mixture
temperature
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019534154A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502228A5 (enExample
JP2020502228A (ja
Inventor
コラソ， アナ マリア ガルシア
フーフェ， ヴォルタ テン
ヨハネス ニコラース クック，
ヨハネス ベ．エム． レヴィンケル，
ヴィルドゥ， サンダー ドゥ
Original Assignee
ミノリックス セラピューティクス エセ．エレ．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ミノリックス セラピューティクス エセ．エレ． filed Critical ミノリックス セラピューティクス エセ．エレ．
Publication of JP2020502228A publication Critical patent/JP2020502228A/ja
Publication of JP2020502228A5 publication Critical patent/JP2020502228A5/ja
Priority to JP2023016009A priority Critical patent/JP2023052918A/ja
Application granted granted Critical
Publication of JP7294661B2 publication Critical patent/JP7294661B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/127—Preparation from compounds containing pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
JP2019534154A 2016-12-23 2017-12-22 ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス Active JP7294661B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023016009A JP2023052918A (ja) 2016-12-23 2023-02-06 ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16382648 2016-12-23
EP16382648.0 2016-12-23
PCT/IB2017/058374 WO2018116281A1 (en) 2016-12-23 2017-12-22 Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023016009A Division JP2023052918A (ja) 2016-12-23 2023-02-06 ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス

Publications (3)

Publication Number Publication Date
JP2020502228A JP2020502228A (ja) 2020-01-23
JP2020502228A5 JP2020502228A5 (enExample) 2021-02-12
JP7294661B2 true JP7294661B2 (ja) 2023-06-20

Family

ID=57799523

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534154A Active JP7294661B2 (ja) 2016-12-23 2017-12-22 ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス
JP2023016009A Withdrawn JP2023052918A (ja) 2016-12-23 2023-02-06 ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016009A Withdrawn JP2023052918A (ja) 2016-12-23 2023-02-06 ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス

Country Status (19)

Country Link
US (2) US11124505B2 (enExample)
EP (1) EP3559010B1 (enExample)
JP (2) JP7294661B2 (enExample)
KR (1) KR102609373B1 (enExample)
CN (1) CN110198945B (enExample)
BR (1) BR112019012972B1 (enExample)
CA (1) CA3046744A1 (enExample)
CY (1) CY1125531T1 (enExample)
DK (1) DK3559010T3 (enExample)
ES (1) ES2926580T3 (enExample)
HR (1) HRP20221067T1 (enExample)
HU (1) HUE059604T2 (enExample)
IL (1) IL267557B (enExample)
LT (1) LT3559010T (enExample)
MX (1) MX379709B (enExample)
PL (1) PL3559010T3 (enExample)
PT (1) PT3559010T (enExample)
SI (1) SI3559010T1 (enExample)
WO (1) WO2018116281A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
HUE071482T2 (hu) 2018-06-06 2025-08-28 Minoryx Therapeutics S L (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.
JP2026500743A (ja) 2022-12-28 2026-01-08 ミノリックス セラピューティクス エセ．エレ． レリグリタゾンの最適投薬
WO2024231881A2 (en) 2023-05-09 2024-11-14 Minoryx Therapeutics S.L. Polymorphic forms and formulations of leriglitazone

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
WO2015150476A1 (en) 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100249988B1 (ko) * 1991-04-11 2000-04-01 로렌스 티. 마이젠헬더 티아졸리딘디온 유도체, 그의 제조방법 및 용도
US5952509A (en) 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
US6067749A (en) 1996-07-11 2000-05-30 Tasmanian Alkaloids Pty. Ltd. Papaver somniferum strain with high concentration of thebaine and oripavine
US5869669A (en) 1996-07-26 1999-02-09 Penick Corporation Preparation of 14-hydroxynormorphinones from normorphinone dienol acylates
HUP0304096A2 (hu) 2003-12-19 2005-08-29 Richter Gedeon Vegyészeti Gyár Rt. Eljárás pioglitazon hidrogénklorid előállítására és intermedierjei
GB0421687D0 (en) 2004-09-30 2004-11-03 Johnson Matthey Plc Preparation of opiate analgesics
ATE447414T1 (de) 2005-02-16 2009-11-15 Micromet Ag Verwendung aktivierter polymere zur trennung von protein- und polypeptid-multimeren
KR20150003766A (ko) * 2012-04-26 2015-01-09 브리스톨-마이어스 스큅 컴퍼니 혈소판 응집을 치료하기 위한 프로테아제 활성화 수용체 4 (par4) 억제제로서의 이미다조티아디아졸 및 이미다조피리다진 유도체
CA2941562C (en) 2013-03-14 2021-09-21 Deuterx, Llc Deuterium-enriched 2,4-thiazolidinediones and methods of treatment
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008038692A1 (en) 2006-09-28 2008-04-03 Banyu Pharmaceutical Co., Ltd. Diaryl ketimine derivative
WO2008136428A1 (ja) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited 含窒素５員複素環化合物
WO2015150476A1 (en) 2014-04-02 2015-10-08 Minoryx Therapeutics S.L. 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
SOHDA T; ET AL，STUDIES ON ANTIDIABETIC AGENTS. XII. SYNTHESIS AND ACTIVITY OF THE METABOLITES OF (PLUS OR 以下備考，CHEMICAL AND PHARMACEUTICAL BULLETIN，日本，PHARMACEUTICAL SOCIETY OF JAPAN，1995年，VOL:43, NR:12，PAGE(S):2168 - 2172，https://pubmed.ncbi.nlm.nih.gov/8582019/，MINUS)-5-[P-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE (PIOGLITAZONE)
TANIS S P; ET AL，SYNTHESIS AND BIOLOGICAL ACTIVITY OF METABOLITES OF THE ANTIDIABETIC ANTIHYPERGLYCEMIC 以下備考，JOURNAL OF MEDICINAL CHEMISTRY，米国，AMERICAN CHEMICAL SOCIETY，1996年，VOL:39, NR:26，PAGE(S):5053 - 5063，http://dx.doi.org/10.1021/jm9605694，AGENT PIOGLITAZONE

Also Published As

Publication number Publication date
IL267557B (en) 2021-10-31
US20190389852A1 (en) 2019-12-26
PT3559010T (pt) 2022-09-01
HUE059604T2 (hu) 2022-11-28
ES2926580T3 (es) 2022-10-27
WO2018116281A1 (en) 2018-06-28
KR102609373B1 (ko) 2023-12-01
HRP20221067T1 (hr) 2022-11-25
US20220204496A1 (en) 2022-06-30
IL267557A (en) 2019-08-29
JP2023052918A (ja) 2023-04-12
KR20190100300A (ko) 2019-08-28
DK3559010T3 (da) 2022-08-15
EP3559010A1 (en) 2019-10-30
PL3559010T3 (pl) 2022-11-21
CN110198945A (zh) 2019-09-03
BR112019012972A2 (pt) 2019-12-31
SI3559010T1 (sl) 2022-10-28
US11731963B2 (en) 2023-08-22
MX379709B (es) 2025-03-11
US11124505B2 (en) 2021-09-21
CN110198945B (zh) 2023-06-27
CY1125531T1 (el) 2026-02-25
LT3559010T (lt) 2022-10-10
MX2019007327A (es) 2019-09-02
CA3046744A1 (en) 2018-06-28
EP3559010B1 (en) 2022-06-08
BR112019012972B1 (pt) 2023-04-18
JP2020502228A (ja) 2020-01-23

Similar Documents

Publication Publication Date Title
JP2023052918A (ja) ５－［［４－［２－［５－（１－ヒドロキシエチル）－２－ピリジニル］エトキシ］フェニル］メチル］－２，４－チアゾリジンジオンおよびその塩を調製するためのプロセス
US8198444B2 (en) Methods for making 3-O-protected morphinones and 3-O-protected morphinone dienol carboxylates
US12145901B1 (en) Process for preparing tetralin compounds
WO2003042180A9 (en) Process for producing optically active oxoheptenoic acid ester
KR20230012494A (ko) 부틸 (5s)-5-(｛2-[4-(부톡시카르보닐)페닐]에틸｝[2-(2-｛[3-클로로-4'-(트리플루오로메틸)[비페닐]-4-일]메톡시｝페닐)에틸]아미노)-5,6,7,8-테트라히드로퀴놀린-2-카르복실레이트의 제조 방법
KR100474202B1 (ko) 티아졸 유도체의 제조방법 및 이를 제조하기 위한 중간체
US9434740B2 (en) Taxane compounds, compositions and methods
HK40013289A (en) Process for preparing thiazolidinedione compounds and salts thereof
HK40014767B (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
HK40014767A (en) Process for preparing 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedione and salts thereof
US20080287663A1 (en) Process For Production Of 4-Biphenylyazetidin-2-Ones
HK40013289B (en) Process for preparing thiazolidinedione compounds and salts thereof
US9309259B2 (en) Process for ixabepilone, and intermediates thereof
US7705155B2 (en) Processes for the production of useful intermediates
JP3565587B2 (ja) １５−ヒドロキシミルベマイシン誘導体の新規合成法
US20200308105A1 (en) Novel method for producing hydroxamic acid derivative, and intermediate therefor
CN106588565A (zh) 一种羟基邻位为卤原子取代的手性仲烯丙醇的合成方法
JPH10168057A (ja) シクロヘキシルアゼチジノン誘導体の製造法
JP2011020944A (ja) ポジトロン放出源化合物の製造方法
HK1119160B (en) Methods for making 3-o protected morphinones and 3-o-protected morphinone dienol carboxylates
JPH11255762A (ja) 光学活性γ−ピロン化合物、その中間体およびそれらの製造方法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201222

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201222

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211125

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220302

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220506

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220608

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20221004

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230206

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230206

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230314

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230403

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230508

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230601

R150 Certificate of patent or registration of utility model

Ref document number: 7294661

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250